S. Mansard

发表

Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.

P. Petrow, N. Basset-Seguin, S. Faivre, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases

A. Veyre, J. Madelmont, Y. Bignon, 2004, The British journal of dermatology.

Eight Years' Experience of Sentinel Lymph Node Biopsy in Melanoma Using Lymphoscintigraphy and Gamma Probe Detection After Radiocolloid Mapping

M. D’Incan, A. Mulliez, I. Barthélémy, 2017, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Metastatic melanoma treated by immunotherapy: discovering prognostic markers from radiomics analysis of pretreatment CT with feature selection and classification

B. Magnin, L. Boyer, Alberto Bartoli, 2022, International Journal of Computer Assisted Radiology and Surgery.

Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy

M. D’Incan, S. Besse, A. Hennino, 2020, Cancer Immunology, Immunotherapy.

Varicella complicated by necrotizing soft tissue infection in childhood: an argument for systematic childhood varicella vaccination in France?

M. D’Incan, I. Barthélémy, A. Depeyre, 2019, European Journal of Dermatology.

Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases.

T. Khalil, X. Durando, P. Verrelle, 2021, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study

L. Misery, C. Robert, L. Chiche, 2019, Arthritis & rheumatology.

Clinical, biological and histological characteristics of bullous pemphigoid associated with anti‐PD‐1/PD‐L1 therapy: A national retrospective study

B. Dréno, G. Jeudy, M. Viguier, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol

X. Durando, J. Chezal, E. Miot-Noirault, 2022, BMC cancer.

Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study

T. Jouary, C. Robert, B. Dréno, 2021, International journal of cancer.

Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.

B. Dréno, O. Dereure, S. Prey, 2019, Journal of immunotherapy.

An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.

J. Grob, C. Lebbé, O. Dereure, 2022, European journal of cancer.

Generalized pustular psoriasis complicated by acute respiratory distress syndrome

J. Bazin, J. Constantin, P. Souteyrand, 2004, The British journal of dermatology.

Response to BRAF and MEK Inhibitors in BRAF Thr599dup-Mutated Melanoma.

L. Machet, L. Mortier, V. Derangère, 2022, JCO precision oncology.

Annexin A1 in primary tumors promotes melanoma dissemination

L. Ouchchane, J. Papon, Jean Kanitakis, 2014, Clinical & Experimental Metastasis.

[Radiation-induced temporary hair loss after endovascular embolization of the cerebral arteries: six cases].

J Chazal, B Irthum, J Gabrillargues, 2002, Annales de dermatologie et de venereologie.

Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group

M. Boubaya, L. Misery, D. Spaeth, 2021, Cancers.

Merkel cell carcinoma: value of sentinel lymph-node status and adjuvant radiation therapy.

S. Albert, X. Sastre-Garau, M. Avril, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Sentinel node status and immunosuppression: recurrence factors in localized Merkel cell carcinoma.

T. Jouary, S. Dalle, P. Stoebner, 2015, Acta dermato-venereologica.

Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 Therapy

D. Cappellen, Siraj M. Ali, C. Robert, 2021, JCO precision oncology.

[Therapeutic strategies and systemic treatment of brain melanoma metastases].

N. Magné, X. Durando, P. Gimbergues, 2013, Bulletin du cancer.

Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.

P. Petrow, M. Boubaya, J. Grob, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.

J. Grob, C. Lebbé, S. Prey, 2020, JAMA dermatology.

Uptake in melanoma cells of N-(2-diethylaminoethyl)-2-iodobenzamide (BZA2), an imaging agent for melanoma staging: relation to pigmentation.

A. Veyre, N. Moins, J. Papon, 2005, Nuclear medicine and biology.

Pregnancy promotes melanoma metastasis through enhanced lymphangiogenesis.

C. Merheb, K. Khosrotehrani, M. Oster, 2011, The American journal of pathology.

Vismodegib efficacy in unresectable trichoblastic carcinoma: a multicenter study of 16 cases.

J. Grob, T. Jouary, H. Maillard, 2021, Journal of American Academy of Dermatology.

Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.

L. Thomas, S. Dalle, Pierre Vabres, 2012, Journal of the American Academy of Dermatology.

[Melanoma of the penis: 6 cases].

M. Avril, P. Souteyrand, A. Spatz, 2004, Annales de dermatologie et de venereologie.

STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.

E. Hindié, S. Chevret, T. Jouary, 2018, The Journal of investigative dermatology.

Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection

P. Dechelotte, M. D’Incan, I. Barthélémy, 2014, The British journal of dermatology.

Tetraspanin8 expression predicts an increased metastatic risk and is associated with cancer-related death in human cutaneous melanoma

L. Barbollat-Boutrand, O. Berthier‐Vergnes, I. Masse, 2021, Molecular cancer.

Annexin A1 in primary tumors promotes melanoma dissemination

L. Ouchchane, J. Papon, Jean Kanitakis, 2014, Clinical & Experimental Metastasis.

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.

J. Grob, C. Robert, C. Lebbé, 2021, European journal of cancer.

Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.

B. Dréno, O. Dereure, S. Prey, 2019, Journal of immunotherapy.

ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy.

P. Ascierto, I. Krajsová, J. Grob, 2019, Journal of Clinical Oncology.

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401

P. Ascierto, R. Dummer, M. Del Vecchio, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature

G. Jeudy, L. Machet, L. Mortier, 2023, Melanoma research.

Safety of immune checkpoint inhibitors for the treatment of melanoma, bronchopulmonary and urologic neoplasms in patients with preexisting autoimmune disease

G. Quéré, D. Cornec, A. Tison, 2017 .

The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma

J. Limacher, M. Barrois, A. Chompret, 2008, British Journal of Cancer.

Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)

S. Prey, A. Khammari, F. Aubin, 2023, Journal of neurology.

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma

A. Fléchon, J. Haroche, N. Labouret, 2023, ESMO open.